Efforts to change the fate of human hematopoietic stem cells (HSC) and progenitor cells (HPC) in-vitro have met with limited success. We hypothesized that previously utilized in-vitro conditions might result in silencing of genes required for the maintenance of primitive HSC/HPC. DNA methylation and histone deacetylation are components of an epigenetic program that regulates gene expression. Using pharmacological agents in-vitro that might possibly interfere with DNA methylation and histone deacetylation we attempted to maintain and expand cells with phenotypic and functional characteristics of primitive HSC/HPC.
Introduction
Modifications of chromatin such as DNA methylation and histone acetylation are important for regulating gene function. [1] [2] [3] [4] Silencing of genes has been shown to be accompanied by DNA methylation of a gene's promoter and by histone deacetylation in the region containing the genes of interest with inhibition of DNA methylation or histone deacetylation reversing the silencing effect. Specific patterns of DNA methylation of genes and histone acetylation are known to be associated with transcriptional regulation and modification of chromatin structure. 5 Histone acetylation has also been shown to have a profound effect on the normal transition from a fetal to an adult hematopoietic cellular differentiation program during ontogeny. 6 Numerous reports have shown that the proliferative and self-renewal capacity of HSC/HPC decreases progressively with differentiation, resulting in cells belonging to specific multiple hematopoietic lineages. 7, 8 There is evidence that early HSC express a promiscuous set of transcription factors and an open chromatin structure required to maintain their multipotentiality, which is progressively quenched as these cells progress down a particular pathway of differentiation. 9 The mechanisms that govern these stem cell fate decisions are likely under tight control but remain potentially alterable. Although the global gene expression profiles for HSC have recently been described, very little is known about the dynamics of gene expression necessary for HSC fate decisions. [10] [11] [12] We hypothesized that these processes associated with differentiation may be mediated by DNA methylation and histone deacetylation allowing stable silencing of a large fraction of the genome thus causing the transcriptional machinery to focus on those genes essential for the expression and maintenance of the differentiated phenotype.
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From 5azacytidine and its analogs as well as histone deacetylase inhibitors (HDACI) each have dramatic effects on transcriptional regulation. [1] [2] [3] [4] These two classes of drugs in combination may be capable of synergistically reactivating developmentally silenced genes. [13] [14] [15] HSC are quiescent cells that are capable of exiting G 0 /G 1 following exposure to early acting cytokines including stem cell factor, FLT-3 ligand and thrombopoeitin. 16, 17 There has been very limited success in controlling this process of HSC commitment and differentiation in vitro beyond HSC undergoing a limited number of cell divisions. 18, 19 We have developed a model system to assess the role of 5aza
2'deoxycytidine (5azaD) and trichostatin A (TSA) in modifying HSC/HPC fate decisions.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From Louis, MO) and 2mmol/L ethylenediamine tetraacetic acid (EDTA). Cells were incubated with hapten-labeled anti-CD34 + monoclonal antibody (mAb) (QBEND-10) in the presence of Fc blocking reagent, and then with anti-hapten coupled to microbeads.
Labeled Cells were filtered through a 30µm nylon mesh and separated using a high gradient magnetic separation column. Magnetically retained cells were then flushed out and used for the experiments. These cells were eluted and stained using mAb against a
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Ex-vivo cultures
To promote cell division of isolated CD34 + cells, a stroma-free suspension culture was established as previously described. 20 Tissue culture dishes (35mm; Costar, Corning, NY) were initially seeded with 1x10 5 CD34 + cells/well in 2.5 mL Iscove modified Dulbecco medium (IMDM) (Biowhittaker) containing 30% FBS and a cocktail of cytokines specifically thought to promote exit from G0/G1 in primitive HSC populations which consisted of 100ng/mL recombinant stem cell factor (SCF), 100ng/mL FLT-3 ligand, 100ng/mL thrombopoietin (TPO) and 50ng/mL of interleukin (IL)-3 (all a gift from Amgen, Thousand Oaks, CA). Cells were maintained in the media and incubated at 37 o C in a 100%-humidified atmosphere containing 5% CO 2 for 48 hours. After an initial 16 hours of incubation cells were then exposed to the demethylating agent 5aza 2'deoxycitidine (5azaD) (Sigma) at a concentration of 10 -6 M.
After 48 hours cells were washed and then equally distributed to new tissue culture dishes in 2.5mL IMDM supplemented with 30% FBS containing cytokines known to promote terminal differentiation of HSC into multiple hematopoietic lineages. The cocktail of cytokines consisted of 100ng/mL of SCF, 50ng/ml of granulocyte-monocyte colonystimulating factor (GM-CSF), 50ng/mL of IL-3, 50ng/ml of IL-6 and 5 units(U)/mL of recombinant erythropoietin (EPO) (Amgen). Cells at this time point were exposed to trichostatin A (TSA) (Sigma) at 5ng/mL and the culture was continued for an additional 7 days. At the end of the culture period viable cells were enumerated using the trypan SCF, 100ng/mL leukemia inhibitory factor (LIF), 50ng/mL IL-3, 50ng/mL IL-6 and 50ng/mL GM-CSF (Amgen). The cultures were fed weekly by replacement of one half of the culture volume with fresh medium containing the above cytokines at 2 times the previously defined concentration. After 5 weeks of culture in a humidified incubator at 37 o C containing 5% CO 2 , the number of CA were ennumerated. The CAFC frequency was computed by means of minimization of chi regression to the cell number at which 37% of wells were negative for CA formation, with 95% statistical precision using LCalc (Limiting dilution calculation) software (Stem Cell Inc., Vancouver, Canada).
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Carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling to assess cell division
Freshly isolated CD34 + cells were labeled for 10 min at 37 o C with 0.5µmol of CFSE (Molecular Probes, Eugene, Or) in DPBS(Biowhittiker) , a cytoplasmic dye that is equally diluted between daughter cells that are a product of a cell division, and washed three times with 10% FBS RMPI 1640. CFSE labeled cells were then cultured as mentioned above for 9 days and were analyzed for a progressive decline of fluorescence intensity, using a FACS Caliber cytometer (BD) on day 5 and day 9 following previously reported protocols.
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NOD/SCID assay for human marrow repopulating cells
Immunodeficient nonobese diabetic/ ltsz-scid/scid (NOD/SCID) mice were purchased from the Jackson Laboratories (Bar Harbor, Maine) and were maintained as previously described. 29 All NOD/SCID mice were kept under sterile conditions in the microisolator cages and were provided with autoclaved food and anti-CD34 (BD).The marrow cells were also plated in methylcellulose as previously described. Hematopoietic colonies were then pooled and stained with mAb against human CD33 and human D45 (BD) to assess the presence of human cells.
Statistical Analysis:
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Statistical significance was determined with the paired student t-test with significance at P<0.05.
RESULTS:
Methylation status of marrow CD34 + with and without 5azaD and TSA treatment
To determine the methylation status of treated and untreated CD34 + marrow cells COBRA was used to quantitate the DNA methylation of a CpG residue located at -256 th position within the -globin promoter region. Primary CD34 + cells (day 0) initially were methylated at this promoter site (90%). These cells were then cultured for 5 days under various conditions outlined (Table 1) . 87% of cells cultured for five days with cytokines alone were methylated suggesting that the status of this promoter was unchanged throughout the culture period. By contrast 58% of the cells treated with cytokines and sequential addition of 5azaD and TSA were methylated after culture (Table 1) indicating that these drugs are capable of altering cellular methylation patterns in vitro. Bisulfite sequence analysis of 5 CpG sites within the -globin gene promoter and 3 CpG sites within the -globin promoter was performed to confirm and extend the results of the COBRA assay. Six clones were sequenced from both the cells exposed to cytokines alone and from the cells exposed to cytokines and sequential 5azaD and TSA. Clones from the cells exposed to cytokines alone were completely methylated (100%) at all sites in all clones. In the cells exposed to sequential 5azaD and TSA 21/30 CpG sites within the -globin promoter were methylated (70%), and 12/18 sites were methylated within the -globin promoter (67%)( Table 1) .
It is important to point out that hypomethylation of the -globin gene promoter likely has little influence on stem cell behavior. These studies were however performed to show that 5azaD with or without TSA was capable of achieving hypomethylation of a known gene.
Phenotype of CD34 + cells following 5azaD and TSA treatment
Next we investigated the phenotype of marrow CD34 + cells prior to and after treatment with cytokines in vitro for a period of 9 days (Table 2) . A 2 step culture system was set up. The cells were initially cultured in cytokines that promote HSC division to ensure their cycling and thus allow theoretically for the incorporation of 5azaD which was added after 16 hours of this culture. At 48 hours TSA was added and the cytokines were changed to a combination which promotes terminal differentiation. (Table 3) . By contrast the CD34 + cells exposed to the same cytokines and sequential 5azaD and TSA retained the primitive HSC phenotype (Table 2 ) resulting in an expansion of CD34 + CD90 + cell numbers (Table 3 ). Cells exposed to cytokines and to either 5azaD or TSA alone had a more limited expansion of CD34 + CD90 + cell numbers (Table 3 ). To show that this effect could not be attributed merely to cytotoxicity, 5-FU was added to cultures instead of the 5azaD and TSA. In vitro 5-FU treatment has previously been utilized to select for primitive human progenitor cells in vitro. 30 The CD34 + CD90 + cell number in the 5-FU treated cultures decreased significantly after 9 days (Table 3 ) so that by day 9 no CD34 + CD90 + cells were observed. Marrow CD34 + cells following 9 days of culture exposed to 5azaD and TSA resulted in a 2.5 fold expansion of the CD34 + CD90 + cell population.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From CFC potential of cells exposed to 5azaD and TSA To ensure that a discordance between phenotype and function of the drug treated progenitor cells did not exist, we evaluated the functional properties of these cells using CFC and CAFC assays which are used to quantitate the number of differentiated and primitive HPC, respectively. In addition, the ability of these various cell populations to engraft in vivo and differentiate into multiple hematopoietic lineages in immunodeficient NOD/SCID mice (SCID repopulating assays) was used as a surrogate assay for cells with marrow repopulating potential, a unique characteristic of primitive HSC.
CD34
+ cells treated with cytokines alone for 9 days contained dramatically reduced numbers of assayable progenitors in comparison to primary cells (Table 4) . By contrast, unfractionated cells from cultures treated with cytokines and sequential 5azaD and TSA had dramatically greater numbers of hematopoietic progenitors than cultures receiving cytokines alone. Significantly, the drug treated cultures contained greater numbers of multilineage progenitor cells than even the primary cells (Table 4) . By contrast, cells assayed from the cultures treated with cytokines and 5-FU contained no assayable hematopoietic progenitor cells. The plating efficiency of CD34 + cells assayed immediately after selection (primary CD34 + cells) was 12.2 ± 0.5%, whereas that of the unfractionated cells, derived from the primary CD34 + cells, after 9 days of culture in cytokines alone was 0.8 ± 0.2%. The plating efficiency of the unfractionated cultured cells (50% CD34 + cells), derived from the primary CD34 + cells, exposed to cytokines in combination with 5azaD and TSA was 9.7 ± 0.2% which was comparable to that of the primary CD34 + (92.5% pure) selected cell population. In order to determine whether the increase in CD34 + CD90 + cells in the culture exposed to 5azaD and TSA was due to a retention of the quiescent population of HSC, we examined the cell division history of CD34 + CD90 + cells generated in vitro using CFSE staining. CD34 + CD90 + present in the culture were analyzed for progressive loss of fluorescence intensity of CFSE after 5 and 9 days of incubation ( Figure 2 ). The CD34 + CD90 + cell population underwent multiple cell divisions after 5 and 9 days of incubation. In fact after 9 days of culture there were no CD34 + CD90 + cells that had not
divided. These studies demonstrate that the phenotype and functional effects attributed to 5azaD and TSA are not due to preservation of quiescent cells but rather occur subsequent to multiple cell divisions by the cultured CD34 + CD90 + cells. In order to determine whether the effect of these pharmacologic agents was directed against the CD34 + CD90 + or CD34 + CD90 -cells, these cell populations were isolated and pretreated individually with 5azaD and TSA and incubated for 9 days as previously described ( (Figure 3 B,C,D,E). Morphological examination of the cells derived from the CD34 + CD90 + cells that were exposed to 5azaD and TSA ( Figure   3F ) revealed that 68% of the cells were blast-like forms while the culture that had been exposed to the same cytokines but no 5azaD and TSA was composed of primarily terminally differentiated cells, macrophages (54%) and normoblasts (44%) ( Figure 3G ).
In addition CD34 + CD90 + as well as CD34 + CD90 -cells obtained after 9 days in culture were assayed for HPC. When plated in methylcellulose these cells formed colonies composed of cells belonging to all blood lineages (Table 6 ). Only the CD34 + CD90
+ subset however, contained CFU-mix colonies and had a far higher plating efficiency in comparison to the CD34 + CD90 -cells (13.2% versus 7.2%). Furthermore the cells generated from the CD34 + CD90 + cells that had been re-isolated from cultures treated with 5azaD and TSA and then cultured in differentiating cytokines alone for an additional 7 days still retained the ability to form colonies in vitro after a total of 16 days of culture (plating efficiency 2.4%) data not shown.
Repopulating potential of cultured cells exposed to 5azaD and TSA
The ability of human HSC to engraft and differentiate into multiple hematopoietic lineages in vivo is an established surrogate functional HSC assay. possess the capacity to self renew and differentiate into multiple hematopoietic lineages throughout the lifespan of an individual. This is a complex process which involves a hierarchy of HSC which can be influenced by a variety of external regulatory factors.
Whether the fate of an individual HSC is determined by random or stochastic events or can actually be defined by external influences remains an important area of investigation. 32, 33 To date attempts to create an in vitro environment which favors HSC self replication rather than commitment and differentiation has resulted in limited success. 7, 16, 19, 30, 34 Although the molecular signature that defines an HSC has recently been described, the patterns of gene expression that lead to HSC self replication rather than commitment remain unkown. 11,12 Primitive HSC are thought to maintain an open chromatin structure that permits access to the entire HSC developmental program while more differentiated cells along the hematopoietic hierarchy are thought to characteristically undergo a stepwise progression of epigenetic events that controls transcriptional events for each stage and class of progenitor cells. 9 HSC promiscuously express a set of transcription factors that are restricted as the process of commitment to a particular pathway of differentiation occurs. 7, 9, 35 These events likely involve the activation and or silencing of yet to be identified groups of pivotal genes.
We have used two classes of drugs, DNA hypomethylating agents (5azaD) and HDACI (TSA) to explore the influences of these agents on decisions determining HSC fate. Hypomethylation is a molecular mechanism by which previously silenced genes can be reactivated while HDACI maintain acetylation of histones thereby altering chromatin structure to promote gene expression. 
Either primary CD34
+ cells or cells cultured in a cytokine combination in the presence or absence of 5azaD and TSA for 9 days were analyzed for their ability to form CAFC. The number of CA was expressed out of 10,000 cells plated. CAFC frequency was computed using minimization by regression to the cell number at which 37% of wells showed negative CAFC growth with 95% statistical precision. The bar graph represents mean ± SE of two experiments done in limiting dilution where each concentration of cells are tested 24 times. Cells were stained for human CD45, CD19, CD41, CD34 to assess multilineage engraftment . A-C indicates the analysis of mice(n=1) that did not receive any human cell graft (negative control), D-F indicates the analysis of the marrow from mice (n=4) receiving cells exposed to cytokines alone. G-I indicates the analysis of the marrow from mice (n=3) receiving cells exposed to 5azaD and TSA. A) isotype negative control B) CD19 PE and CD45 FITC negative control C) CD34 PE and CD45 FITC negative control D) isotype cytokines alone E) CD19 PE and CD45 FITC cytokines alone F) CD34 PE and CD45 FITC exposed to cytokines alone. G) isotype for exposed to 5azaD and TSA H) CD 19PE and CD45 FITC of cells exposed to 5azaD and TSA I) CD34 PE and CD45 FITC of exposed to 5azaD and TSA. Table shows phenotype of CD34 + cells prior to and after exposure to 5 azaD and TSA. Each number represents the mean of 3 experiments ± the standard error of the mean. *Lineage negative represents those cells that do not express phenotypic markers associated with terminally differentiated cells (CD2, CD14, CD15, CD16 , CD19 Glycophorin A). 1. There is a significant increase in the percent of CD90 + in the cytokines and sequential 5azaD and TSA treated culture when compared with the primary cells (P<0.01, student paired t-test). 2. There was no significant difference between the two cell populations as related to the expression of CD38, CD 117 and lineage markers. + in each condition ± the standard error of the mean.. 1. Each number represents the mean of 2 experiments ± the standard error of the mean. 2. Plating efficiency is defined as total number of hematopoietic colonies/ total cells plated x 100. 3.There is a significant increase in the total number of colonies when sequential addition of 5azaD and TSA are compared to cytokines alone( P<0.01). Table showing the number of colonies after plating marrow cells from mice that received human grafts 7 weeks earlier.
1. The estimated number of human colonies is determined by the percent of human cells composing the pooled hematopoietic colonies from group of mice which stained positively with mAb against CD45/CD33 antibodies using FACS analysis multiplied by the total number of colonies enumerated. For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
